Experience

Noema Pharma

• Switzerland
• Biotechnology
• 1 - 100 Employee

• Executive Consultant

  • May 2023 - Present



atai Life Sciences/ Perception Neuroscience

• Boston, Massachusetts, United States

• Consultant

  • Apr 2022 - Jun 2023



Karyopharm Therapeutics Inc.

• United States
• Pharmaceutical Manufacturing
• 200 - 300 Employee

• Senior Vice President, Global Medical Scientific Medical Affairs, Customer Excellence and Operations

  • 2021 - Oct 2021



Sunovion Pharmaceuticals

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Executive Vice President, Chief Commercial Officer

  • 2016 - 2019

  Appointed by Management Committee of Osaka, Japan-based parent company, Sumitomo Dainippon Pharma Co., Ltd. (Sumitomo), to lead Sunovion Commercial Organization, including operations in US, Canada, and Europe, with 1700+ employees worldwide. Responsible for all Commercial functions enterprise wide, including Sales, Marketing, Strategy, Finance, Forecasting, Operations, and Managed Markets. Represented Sunovion at quarterly Sumitomo Investor Relations meetings, Sumitomo Management… Show more Appointed by Management Committee of Osaka, Japan-based parent company, Sumitomo Dainippon Pharma Co., Ltd. (Sumitomo), to lead Sunovion Commercial Organization, including operations in US, Canada, and Europe, with 1700+ employees worldwide. Responsible for all Commercial functions enterprise wide, including Sales, Marketing, Strategy, Finance, Forecasting, Operations, and Managed Markets. Represented Sunovion at quarterly Sumitomo Investor Relations meetings, Sumitomo Management Committee meetings, and Sunovion Board of Directors meetings.

• Senior Vice President, Chief Commercial Officer

  • 2014 - 2016

  Led all Commercial Functions, including Sales, Marketing, Managed Markets, and Operations. Responsible for Global Operations including Canada and European Subsidiaries. Promoted to lead newly created Neuroscience Business Unit comprising LATUDA; Lunesta® (eszoplicone), indicated for the treatment of Insomnia; and dasotraline, a DNRI under investigation for treatment of moderate-to-severe Binge Eating Disorder (BED). Member of Joint Commercial Committee (JCC) responsible for… Show more Led all Commercial Functions, including Sales, Marketing, Managed Markets, and Operations. Responsible for Global Operations including Canada and European Subsidiaries. Promoted to lead newly created Neuroscience Business Unit comprising LATUDA; Lunesta® (eszoplicone), indicated for the treatment of Insomnia; and dasotraline, a DNRI under investigation for treatment of moderate-to-severe Binge Eating Disorder (BED). Member of Joint Commercial Committee (JCC) responsible for oversight of licensing agreement with Takeda for European rights to LATUDA. London, UK-based European subsidiary, Sunovion Pharmaceuticals Europe Ltd. (SPE) retained rights to LATUDA in UK. • Led expansion of LATUDA into mood disorders with launch of two new indications in Bipolar I Depression

• Senior Vice President Global Marketing and US Sales

  • 2013 - 2014

  Led Sales and Marketing in the US for Latuda. My responsibilities also include Global Marketing.

• Vice President US and Global CNS Marketing

  • 2009 - 2013

  Led prelaunch and launch commercialization for Latuda, Sunovion/DSP flagship product in the US. My new appointment includes both U.S. and Global commercial responsibilities.



Forest Laboratories (now Allergan)

• Pharmaceutical Manufacturing
• 500 - 600 Employee

• Assistant Vice President

  • Feb 2007 - Feb 2009

  Led Lexapro and Vraylar (cariprazine), developed for schizophrenia and bipolar disorder. Led Lexapro and Vraylar (cariprazine), developed for schizophrenia and bipolar disorder.



Pfizer

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Senior Group Leader CNS/Antipsychotics (Geodon/asenapine)

  • 1998 - 2007